AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA BioTech ADVB Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus July 23, 2026 — 10:45 pm EDT Written by RTTNews.com for RTTNews -> (RTTNews) - Today's top biotech gainers include Advanced Biomed, which led the rally with a gain of more than 200% over the past week. Novocure climbed following strong Q2 results and a revised full-year revenue outlook, while Medpace gained on solid quarterly performance and a positive outlook, among others. Read on… ADVB Delivers a 200%+ Weekly Gain Shares of Advanced Biomed Inc. (ADVB) have rallied as much as 211% this week, soaring from $6.71 at the start of the week to an intraday high of $20.87 on Thursday. The company focuses on integrating multiple interdisciplinary technologies and has established its own microfluidic technology platform. Its products are designed to provide rapid, accurate, and affordable diagnostic assays and services for cancer patients, with regulatory approvals underway in Taiwan and plans to expand into global markets. The company has not yet commenced commercial sales of its products and currently does not generate revenue from product sales. A 1-for-20 reverse stock split was implemented on February 20, 2026, to regain Nasdaq compliance. On July 20, 2026, Advanced Biomed withdrew the Registration Statement it had filed with the SEC on July 23, 2025. The registration statement would have enabled Helena Global Investment Opportunities I Ltd. to resell up to $25 million of Advanced Biomed's common stock over time, subject to applicable securities laws. ADVB closed Thursday's trading at $16.78, up 36.98%. NVCR Lifts Revenue Outlook Novocure (NVCR), a global oncology company, surged more than 28% on Thursday after reporting strong financial results for the second quarter ended June 30, 2026, and raising its full-year revenue guidance. The company commercializes its innovative Tumor Treating Fields (TTFields) therapy, which is approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM). Total net revenues increased 16% year over year to $183.6 million in the second quarter of 2026, driven by continued adoption of TTFields therapy. Reflecting the strong performance, Novocure raised its full-year 2026 total net revenue guidance to $710 million-$725 million, up from its previous outlook of $690 million-$710 million. Total net revenues for 2025 were $655.4 million. NVCR closed Thursday's trading at $19.99, up 28.39%. SPRC Soars 20% SciSparc Ltd. (SPRC) was one of the top gainers on Thursday, with shares gaining more than 20% on no specific news. Through its majority-owned subsidiary NeuroThera, the company is engaged in the development of clinical-stage pharmaceutical products. SciSparc focuses on building and advancing a portfolio of cannabinoid-based pharmaceutical technologies and assets to address unmet medical needs. Earlier in the month, the company announced the initiation of its Phase 2b clinical trial at Hannover Medical School, Hanover, Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults. SPRC closed Thursday's trading at $5.72, up 20.17%. MEDP Delivers Steady Progress Medpace Holdings Inc. (MEDP) gained more than 14%, following its second-quarter financial results and rosy outlook for the year. The company is a global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Revenue for the three months ended June 30, 2026, increased 17.2% to $707.3 million, compared to $603.3 million for the comparable prior-year period. For full-year 2026, the company forecasts revenue in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14.0% over 2025 revenue of $2.530 billion. MEDP closed Thursday's trading at $605.82, up 14.71%. AGEN On Watch Agenus Inc. (AGEN) gained more than 11% on Thursday on no specific news. Earlier in the month, the company announced an oversubscribed private placement of up to $340 million to support its planned registrational Phase 3 ROBBIN trial evaluating neoadjuvant botensilimab plus balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer. The first patient in the ROBBIN trial is expected to be dosed in Q1 2027, with interim pathologic response data to be released in the second half of 2027. An interim analysis of event-free survival (EFS) is anticipated in the second half of 2029, with the final EFS analysis expected in the second half of 2030. AGEN closed Thursday's trading at $6.19, up 11.9